Stemline Therapeutics (NASDAQ:STML) -20.4% after-hours after announcing preliminary net revenues for Q4 and the full year.
STML estimates Q4 revenues for Elzonris, its treatment of adult and pediatric patients with blastic plasmacytoid dendritic cell neoplasm, totaled $11.8M, while FY 2019 revenues came in at $43.2M.
“Given the orphan nature and unique features of this disease, we believe patient starts were subject to significant quarterly variance – a phenomena that will likely continue throughout 2020,” the company says.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.